Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Serum matrix metalloproteinase-3 in comparison with acute phase proteins as a marker of disease activity and radiographic damage in early rheumatoid arthritis.

Ally MM, Hodkinson B, Meyer PW, Musenge E, Tikly M, Anderson R.

Mediators Inflamm. 2013;2013:183653. doi: 10.1155/2013/183653. Epub 2013 Apr 7.

2.

Biomarkers predict radiographic progression in early rheumatoid arthritis and perform well compared with traditional markers.

Young-Min S, Cawston T, Marshall N, Coady D, Christgau S, Saxne T, Robins S, Griffiths I.

Arthritis Rheum. 2007 Oct;56(10):3236-47.

4.
5.
6.

Increased serum amyloid A and its association with autoantibodies, acute phase reactants and disease activity in patients with rheumatoid arthritis.

Shen C, Sun XG, Liu N, Mu Y, Hong CC, Wei W, Zheng F.

Mol Med Rep. 2015 Feb;11(2):1528-34. doi: 10.3892/mmr.2014.2804. Epub 2014 Oct 29.

PMID:
25352049
7.
8.

Baseline serum level of matrix metalloproteinase-3 as a biomarker of progressive joint damage in rheumatoid arthritis patients.

Galil SM, El-Shafey AM, Hagrass HA, Fawzy F, Sammak AE.

Int J Rheum Dis. 2016 Apr;19(4):377-84. doi: 10.1111/1756-185X.12434. Epub 2014 Oct 7.

PMID:
25292349
9.
10.

Serum matrix metalloproteinase-3 as predictor of joint destruction in rheumatoid arthritis, treated with non-biological disease modifying anti-rheumatic drugs.

Mamehara A, Sugimoto T, Sugiyama D, Morinobu S, Tsuji G, Kawano S, Morinobu A, Kumagai S.

Kobe J Med Sci. 2010 Sep 30;56(3):E98-107.

11.

High serum cartilage oligomeric matrix protein determines the subset of patients with early-stage rheumatoid arthritis with high serum C-reactive protein, matrix metalloproteinase-3, and MRI-proven bone erosion.

Fujikawa K, Kawakami A, Tamai M, Uetani M, Takao S, Arima K, Iwamoto N, Aramaki T, Kawashiri S, Ichinose K, Kamachi M, Nakamura H, Origuchi T, Ida H, Aoyagi K, Eguchi K.

J Rheumatol. 2009 Jun;36(6):1126-9. doi: 10.3899/jrheum.080926. Epub 2009 May 15.

PMID:
19447929
12.

Serum matrix metalloproteinase 3 in early rheumatoid arthritis is correlated with disease activity and radiological progression.

Posthumus MD, Limburg PC, Westra J, van Leeuwen MA, van Rijswijk MH.

J Rheumatol. 2000 Dec;27(12):2761-8.

PMID:
11128661
13.
14.

Serum matrix metalloproteinase-3 and fibrin degradation product levels correlate with clinical disease activity in rheumatoid arthritis.

Ichikawa Y, Yamada C, Horiki T, Hoshina Y, Uchiyama M.

Clin Exp Rheumatol. 1998 Sep-Oct;16(5):533-40.

PMID:
9779299
15.

Circulating cytokine profiles and their relationships with autoantibodies, acute phase reactants, and disease activity in patients with rheumatoid arthritis.

Meyer PW, Hodkinson B, Ally M, Musenge E, Wadee AA, Fickl H, Tikly M, Anderson R.

Mediators Inflamm. 2010;2010:158514. doi: 10.1155/2010/158514. Epub 2011 Mar 2.

16.

Acute-phase serum amyloid A regulates tumor necrosis factor α and matrix turnover and predicts disease progression in patients with inflammatory arthritis before and after biologic therapy.

Connolly M, Mullan RH, McCormick J, Matthews C, Sullivan O, Kennedy A, FitzGerald O, Poole AR, Bresnihan B, Veale DJ, Fearon U.

Arthritis Rheum. 2012 Apr;64(4):1035-45. doi: 10.1002/art.33455. Epub 2011 Nov 10.

18.

Elevation of serum matrix metalloproteinase-3 as a predictive marker for the long-term disability of rheumatoid arthritis patients in a prospective observational cohort IORRA.

Shinozaki M, Inoue E, Nakajima A, Hara M, Tomatsu T, Kamatani N, Yamanaka H.

Mod Rheumatol. 2007;17(5):403-8. Epub 2007 Oct 19.

PMID:
17929133
19.

[Relationship between matrix metalloproteinase-3 levels and articular destructive changes in early and extended rheumatoid arthritis].

Avdeeva AS, Aleksandrova EN, Karateev DE, Panasyuk EY, Smirnov AV, Cherkasova MV, Nasonov EL.

Ter Arkh. 2016;88(5):13-18. doi: 10.17116/terarkh201688513-18. Russian.

PMID:
27239921
20.

Baseline serum MMP-3 levels in patients with Rheumatoid Arthritis are still independently predictive of radiographic progression in a longitudinal observational cohort at 8 years follow up.

Houseman M, Potter C, Marshall N, Lakey R, Cawston T, Griffiths I, Young-Min S, Isaacs JD.

Arthritis Res Ther. 2012 Feb 7;14(1):R30. doi: 10.1186/ar3734.

Supplemental Content

Support Center